Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30117442 | 0.86 | TGFBR1 (0.41) | TGFBR1LRRK2KCNH2PIK3CAMTOR | |
| SCHEMBL15639216 | 0.86 | TGFBR1 (0.41) | TGFBR1LRRK2KCNH2PIK3CAMTOR | |
| SCHEMBL15639201 | 0.82 | TGFBR1 (0.40) | TGFBR1LRRK2KCNH2PIK3CAMTOR | |
| SCHEMBL15639572 | 0.75 | TGFBR1 (0.52) | TGFBR1LRRK2PIK3CAPIK3C3ALOX5AP | |
| SCHEMBL15639399 | 0.75 | TGFBR1 (0.54) | TGFBR1LRRK2KCNH2PIK3CAPIK3C3 | |
| SCHEMBL15639548 | 0.73 | TGFBR1 (0.44) | TGFBR1PIK3CAPIK3C3PDE10A | |
| SCHEMBL30117430 | 0.73 | TGFBR1 (0.58) | TGFBR1PDE10A | |
| SCHEMBL15639428 | 0.73 | TGFBR1 (0.58) | TGFBR1PDE10A | |
| SCHEMBL15640074 | 0.73 | TGFBR1 (0.49) | TGFBR1PIK3CAPIK3C3ALOX5APFEN1 | |
| SCHEMBL15639894 | 0.73 | TGFBR1 (0.52) | TGFBR1PIK3CAPIK3C3ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885LRRK2 477/4885KCNH2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.